NEPHROS INC NEPH
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
-26.46
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $18.8M | $1.2M | $11.6M | — | $10.2M |
| 2024 | $14.2M | $74,000 | $8.7M | -$547,000 | $8.6M |
| 2023 | $14.2M | -$1.6M | $8.4M | $752,000 | $8.4M |
| 2022 | $10.0M | — | $4.7M | -$3.4M | $8.9M |
| 2021 | $10.2M | -$3.9M | $5.6M | -$1.5M | $14.7M |
| 2020 | $8.6M | -$4.5M | $4.9M | -$7.1M | $15.6M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -26.46 (distress)
- Working capital / assets 0.62
- Retained earnings / assets -10.493
- EBIT / assets 0.084
- Equity / liabilities 2.967
Source: SEC EDGAR filings · CIK 0001196298 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.